Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung Cancer

16 de novembro de 2026 atualizado por: Oliver Jonas

Pilot Study of an Implantable Microdevice for in Situ Evaluation of Drug Responses in Lung Cancer

This research is being done to study the safety and feasibility of implanting and retrieving a microdevice that releases microdoses of 20 specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against lung cancer or mesothelioma.

The name of the intervention(s) involved in this study are:

Implantable Microdevice (IMD) Surgery (excision of tumor) Drugs used in this study will include drugs already used as standard of care for the treatment of lung cancer and mesothelioma, or other drugs that are approved or being investigated for these indications.

Visão geral do estudo

Status

Recrutamento

Condições

Intervenção / Tratamento

Descrição detalhada

This pilot research study is being conducted to evaluate the safety and feasibility of implanting and retrieving investigational drug-releasing microdevices in tumors of patients with lung cancer or malignant mesothelioma. The study will also explore the potential of these microdevices as a tool to assess how individual tumors respond to multiple anticancer drugs and drug combinations.

The microdevices are designed to release very small quantities (microdoses) of selected anticancer drugs directly into spatially distinct regions of a tumor. The drugs evaluated may include treatments currently approved for lung cancer or mesothelioma, as well as drugs approved for other cancer types that are being investigated as potential treatments for these diseases. The purpose of this localized drug exposure is to measure biological responses within the tumor tissue, rather than to provide therapeutic treatment.

The study involves implanting one or more microdevices, each small enough to fit within the tip of a needle, directly into an accessible tumor. The microdevices release microdoses of anticancer drugs through passive diffusion into the surrounding tumor tissue. Drug exposure is intended to remain localized to small regions of the tumor, with minimal systemic exposure.

After approximately 3 days, the microdevices and small regions of surrounding tumor tissue will be retrieved through a planned biopsy or surgical procedure. The collected tissues will be analyzed to evaluate local tumor responses to the individual drugs or drug combinations, including changes in tumor cell viability, cell death, and other biological markers of drug activity.

Research procedures may include screening for eligibility, clinical evaluations, imaging studies, microdevice implantation, tumor tissue sampling, blood collection, and follow-up visits.

The primary objectives of the study are to evaluate the safety and technical feasibility of microdevice implantation, localized drug delivery, and device retrieval in patients with lung cancer or mesothelioma. Exploratory objectives include characterizing tumor responses to multiple anticancer drugs and identifying biological markers associated with drug sensitivity or resistance.

The microdevice is investigational and has not been approved by the U.S. Food and Drug Administration (FDA) for the treatment of any disease. The microdevice-based drug testing procedure is experimental and is not intended to provide direct therapeutic benefit to participants.

Participation in this research study is expected to last up to 4 months.

Approximately 20 participants are expected to enroll, including 10 participants in each of two study cohorts.

Tipo de estudo

Intervencional

Inscrição (Estimado)

20

Estágio

  • Fase inicial 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

Locais de estudo

    • Massachusetts
      • Boston, Massachusetts, Estados Unidos, 02115
        • Recrutamento
        • Brigham and Women's Hospital
        • Contato:

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Patients must have the ability to understand and the willingness to sign a written informed consent document.

  • Participants must have confirmed or suspected lung cancer or mesothelioma or other intrathoracic malignancy, and are planned for surgical resection of the tumor as part of their standard clinical care.

  • Participants must be 18 years of age or older.

  • Participants must be evaluated by a medical oncologist or surgeon who will determine the clinically appropriate treatment strategy based on clinical history and extent of disease.

  • Patients must be deemed medically stable to undergo both percutaneous procedures and standard-of-care surgical procedures.

  • Participants will undergo laboratory testing within 30 days prior to the procedure (or within 72 hours if there has been a change in the clinical status since the initial blood draw). Patients must have absolute neutrophil count ≥1,000/mcL, platelets ≥120,000/mcL, Prothrombin time (PT) (International Normalized Ratio) 1.5 and Partial Thromboplastin Time (PTT) <1.5x control.

  • Participants must have undergone computed tomography (CT), magnetic resonance imaging (MRI)) or other clinical imaging that assesses the extent of disease and allows the research team to assess for study eligibility. This will have been done as part of the standard-of-care.

  • The participant's case must be reviewed by representatives of interventional radiology and the appropriate surgical subspecialty to assess the following factors:

    • Patient is clinically stable to undergo microdevice implantation and surgical procedures.
    • Patient has sufficient volume of disease to allow implantation of the microdevice.
    • Patient has a lesion for which the microdevice is a) amenable to percutaneous placement, and b) amenable to removal at the time of surgery.
  • Patients must be willing to undergo research-related genetic sequencing (somatic and germline) and data management, including the deposition of de-identified genetic sequencing data in NIH central data repositories.

Exclusion Criteria:

  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable cardiac arrhythmia, or psychiatric illness/social situations that would limit the safety of a biopsy and/or surgery.
  • Uncorrectable bleeding or coagulation disorder known to cause increased risk with surgical or biopsy procedures (detailed below).

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Diagnóstico
  • Alocação: N / D
  • Modelo Intervencional: Atribuição de grupo único
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Implantable Microdevice (IMD) + Standard-of-care Surgical Retrieval + Standard-of-Care Treatment

Participants with confirmed or suspected lung cancer or malignant mesothelioma who are candidates for standard-of-care surgical tumor resection will be eligible for study participation and will undergo the following study procedures:

  • **Microdevice implantation:** Placement of 1-4 investigational drug-releasing microdevices into an accessible tumor approximately 72 ± 24 hours prior to scheduled standard-of-care surgery. Microdevices may be implanted using image-guided percutaneous techniques or other clinically appropriate approaches, depending on tumor location and accessibility. The number of microdevices implanted will be determined on a case-by-case basis based on tumor characteristics, anatomical location, procedural feasibility, and participant-specific considerations.
  • **Microdevice retrieval and tissue collection:** At the time of scheduled standard-of-care surgery, the implanted microdevices will be surgically retrieved along with surrounding tumor tissue and analyzed.

Small, implantable device with 20 microreservoirs for drug and drug combinations, via needle, percutaneously, and guided by interventional radiologic techniques. Drugs will include selected anticancer agents, such as methotrexate, gemcitabine, pemetrexed, paclitaxel, ipilimumab, nivolumab, pembrolizumab, carboplatin, abemaciclib, vinorelbine, etoposide, and osimertinib.

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Safety of microdevice implantation and indwelling
Prazo: up to 30 days

Any grade 4-5 adverse events likely or definitely attributable to device placement, indwelling or retrieval Any death attributable to the study procedures and not attributable to the underlying malignancy or external causes Any device or microdose drug adverse effect resulting in major adverse events as defined in the protocol

up to 30 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Feasibility of assessing tissue responses from microdevice treated tumor regions
Prazo: 14 days

Investigators will assess the technical feasibility of retrieving and processing the microdevices with surrounding tissue for downstream research analysis. A device retrieval is defined as successful if at least half of the reservoirs are surrounded by at least 500 microns of tissue.

14 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Investigador principal: Raphael Bueno, MD, Brigham and Women's Hospital

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

16 de novembro de 2026

Conclusão Primária (Estimado)

16 de novembro de 2030

Conclusão do estudo (Estimado)

30 de novembro de 2031

Datas de inscrição no estudo

Enviado pela primeira vez

17 de outubro de 2026

Enviado pela primeira vez que atendeu aos critérios de CQ

17 de outubro de 2026

Primeira postagem (Real)

23 de outubro de 2026

Atualizações de registro de estudo

Última Atualização Postada (Real)

18 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • 26-320

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: Oliver Jonas, PhD. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Prazo de Compartilhamento de IPD

Data can be shared no earlier than 1 year following the date of publication.

Critérios de acesso de compartilhamento IPD

Contact the Partners Innovations team at http://www.partners.org/innovation.

Tipo de informação de suporte de compartilhamento de IPD

  • PROTOCOLO DE ESTUDO
  • SEIVA
  • CIF

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .